Founded Year
2005Stage
Unattributed VC - III | AliveTotal Raised
$53.66MLast Raised
$34.05M | 5 yrs agoAbout OxThera
OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera's intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.
OxThera Headquarter Location
Regeringsgatan 111
Stockholm, 111 39,
Sweden
+46 8 660 02 23
Expert Collections containing OxThera
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
OxThera is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
OxThera Patents
OxThera has filed 16 patents.
The 3 most popular patent topics include:
- Kidney diseases
- Oxalates
- Gastrointestinal tract disorders
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/27/2018 | 4/27/2021 | Ion channels, Kidney diseases, Rare diseases, Gastrointestinal tract disorders, Autosomal recessive disorders | Grant |
Application Date | 9/27/2018 |
|---|---|
Grant Date | 4/27/2021 |
Title | |
Related Topics | Ion channels, Kidney diseases, Rare diseases, Gastrointestinal tract disorders, Autosomal recessive disorders |
Status | Grant |
Latest OxThera News
Jun 14, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adamis, Astrazeneca, Celltrion, Daiichi, Eyegate, G1, Immvira, Novan, Novavax, Oxthera, Precigen, Roche, Scholar Rock, Terns, Tyme, Vertex, Zynerba.
OxThera Web Traffic
OxThera Rank
When was OxThera founded?
OxThera was founded in 2005.
Where is OxThera's headquarters?
OxThera's headquarters is located at Regeringsgatan 111, Stockholm.
What is OxThera's latest funding round?
OxThera's latest funding round is Unattributed VC - III.
How much did OxThera raise?
OxThera raised a total of $53.66M.
Who are the investors of OxThera?
Investors of OxThera include Kurma Partners, Industrifonden, IDInvest Partners, Life Sciences Partners, Sunstone Capital and 10 more.
Who are OxThera's competitors?
Competitors of OxThera include Cerecin, MaxCyte, NGM Biopharmaceuticals, Pique Therapeutics, BIND Therapeutics and 11 more.
You May Also Like
EnzymeRx is a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role.
Antoxis is a Scotland (Aberdeen) based biotechnology company focused on therapeutic antioxidants. The company's products aim to target and destroy damaging free radicals that are generated in excessive amounts in a number of clinical conditions. The company's initial focus is neurodegeneration, in particular ischaemic stroke and Alzheimer's disease.
AngioChem is a clinical-stage biotechnology discovering and developing drugs that are capable of crossing the blood-brain barrier to treat brain diseases. The company's EPiC platform aims to solve the key problem for crossing the blood-brain barrier by developing drugs that use a receptor-based approach.
Halsa Pharmaceuticals is a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases.
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's core technology is based on research which showed that in many neuropathic pain conditions, the signal that triggers pain actually arises at the level of the skin. This finding provides a strong biological rationale for developing topically delivered drugs to target the pain at the source - the pain receptors in the skin. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain.ARC-4558 is a topical 0.1% clonidine gel being developed for the treatment of painful diabetic neuropathy (PDN). It is a clear, water-based, fast-drying gel that provides pain relief that rivals approved oral drugs. ARC-4558 has a minimal side-effect profile with low/undetectable systemic levels of clonidine with over 600 patients treated in clinical trials to date.
Pique Therapeutics is a biotechnology company focused initially on the treatment of cancer. Pique's lead product is a therapeutic vaccine for non-small cell lung cancer in Phase 2 clinical trials. Pique is also utilizing its therapeutic vaccine technology in additional areas of oncology, with products in pre-clinical stage for pancreatic, colorectal, and head and neck cancers.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.